BICYCLE THERAPEUTICS PLC
BCYC$759M
Small CapNASDAQPharmaceutical Preparations🇺🇸North AmericaCAMBRIDGE305 employees
Drugs in Pipeline
5
Phase 3 Programs
2
Upcoming Catalysts
2
Next Catalyst
Jul 31, 2026
15wMarket Overview
Stock performance and key metrics
BCYC News
Catalyst Timeline
2 upcoming, 2 past
Drug Pipeline
BT8009
Urinary Bladder Neoplasm
Gemcitabine + cisplatin Or carboplatin
Metastatic Urothelial Cancer
Zelenectide pevedotin (BT8009)
Non-Small Cell Lung Cancer
BT5528
Advanced Solid Tumor Historically Known for High EphA2 Expression
BT7480
Advanced Solid Tumor
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
BT8009 | Phase 3 | Urinary Bladder Neoplasm | - | - |
Gemcitabine + cisplatin Or carboplatin | Phase 3 | Metastatic Urothelial Cancer | - | - |
Zelenectide pevedotin (BT8009) | Phase 2 | Non-Small Cell Lung Cancer | - | - |
BT5528 | Phase 2 | Advanced Solid Tumor Historically Known for High EphA2 Expression | - | - |
BT7480 | Phase 2 | Advanced Solid Tumor | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply